Semaglutide and tirzepatide may be cost-effective for knee osteoarthritis in patients with obesity
1. In this microsimulation model, the two glucagon-like peptide-1 receptor agonists were shown to be cost-effective when added to usual ...
Tag: glucagon-like peptide-1 (GLP-1) receptor agonists
Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors associated with similar dementia risk in older adults
1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) did not significantly affect the risk of dementia ...
Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
1. In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher ...
Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss
1. In this post-hoc analysis of the SURMOUNT-1 trial, there was a mostly linear relationship between percentage change in weight ...
Semaglutide may improve cardiovascular outcomes versus empagliflozin in patients with diabetes
1. In this retrospective cohort study, treatment with semaglutide resulted in nominally lower incidence of the composite of death, myocardial ...
Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events ...
Glucagon-like peptide-1 receptor agonists associated with lower depression risk in older adults with diabetes
1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of depression compared ...
Glucagon-like peptide-1 receptor agonists and co-agonists safe and effective for weight loss
1. In this systematic review, glucagon-like peptide-1 receptor agonists and co-agonists were effective in inducing weight loss in overweight adults ...
Semaglutide improves symptoms and function in obesity-related heart failure
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer ...
Semaglutide improves cardiovascular outcomes in obese patients without diabetes
1. In this randomized-controlled trial, the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide reduced the risk of cardiovascular death, myocardial infarction, ...
